OT 4003

Drug Profile

OT 4003

Latest Information Update: 09 Nov 2000

Price : $50

At a glance

  • Originator LEO Pharma
  • Class Antiasthmatics; Hexanoic acids; Quinolines
  • Mechanism of Action Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 09 Nov 2000 Discontinued-Preclinical for Asthma in Denmark (Unknown route)
  • 23 Jul 1998 No-Development-Reported for Asthma in Denmark (Unknown route)
  • 03 Jan 1996 An in vitro and in vivo study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top